Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05489289 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

StatusRecruiting
PhasePhase 3
SponsorAkeso
Started2023-01-05
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 12, 2025 (before its estimated January 28, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-03-11
Not Yet Recruiting→Recruiting Study Status, Study Design, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-01-28→2026-01-28
Completion date2026-11-01→2027-01-01
Start dateestimated 2022-09-24→confirmed 2023-01-05
Enrollment target405→570
Study sitesdetails revised at 1 of 1 site
2022-08-04
Original filing
Akeso
96 trials monitored
See 1 trial at risk
Liver Cancer
1,505 trials monitored
See 60 trials at risk
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
Trial Details
NCT Number NCT05489289
Lead Sponsor Akeso
Conditions Hepatocellular Carcinoma
Enrollment 570 participants
Start Date 2023-01-05
Primary Completion 2026-01-28 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-12